Almirall Licenses an Anti-IL-21 Monoclonal Antibody From Novo Nordisk to Develop It as a First-in-Class Agent in Dermatology
BARCELONA, Spain–(BUSINESS WIRE)–Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, announced today that it has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828. Under the agreement, Almirall obtains global rights to develop and commercialize this monoclonal antibody in certain fields, including immune inflammatory dermatological diseases. Almirall will accelerate the development